Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1
AbstractContext Cholangiocarcinoma with highly heterogeneous, aggressive, and multidrug resistance has a poor prognosis. Although babaodan (BBD) combined with cisplatin improved non-small cell lung cancer efficacy, its impact on overcoming resistance in cholangiocarcinoma remains unexplored.Objectiv...
Saved in:
Main Authors: | Jiong Li (Author), Xiangjun Ma (Author), Faying Xu (Author), Yuanliang Yan (Author), Weiqing Chen (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Piezo 1 activation facilitates cholangiocarcinoma metastasis via Hippo/YAP signaling axis
by: Biqiang Zhu, et al.
Published: (2021) -
Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression
by: Meijia Qian, et al.
Published: (2021) -
Fisetin Inhibits Osteogenic Differentiation of Mesenchymal Stem Cells via the Inhibition of YAP
by: Chanchao Lorthongpanich, et al.
Published: (2021) -
Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma
by: Manida Suksawat, et al.
Published: (2022) -
Scopoletin potentiates the anticancer effects of cisplatin against cholangiocarcinoma cell lines
by: Md. Ali Asgar, et al.
Published: (2015)